What Orchid Chemicals & Pharmaceuticals Ltd. does

Orchid Chemicals & Pharmaceuticals Ltd. (operating as OrchidPharma Ltd) is a vertically integrated pharmaceutical company founded in 1992 as an export-oriented unit and headquartered in Chennai, India. The company spans the entire pharmaceutical value chain from discovery to delivery, with established capabilities in research, manufacturing, and marketing across multiple therapeutic domains including anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular, nutraceuticals, and oral and sterile products. Its core product portfolio comprises Active Pharmaceutical Ingredients (APIs) and finished dosage forms, positioning it as a B2B supplier serving approximately 50 pharmaceutical companies in India through alliances and partnerships with globally reputed majors. The company employs between 1,001 and 5,000 people and maintains a claimed global footprint across Asia.

The company's recent history is defined by a Corporate Insolvency Resolution Process (CIRP) initiated at the NCLT Chennai Bench on February 28, 2018. Following resolution proceedings and approval from NCLAT and interim orders from the Supreme Court, the resolution plan was implemented on March 31, 2020, with Dhanuka Laboratories Limited emerging as the resolution applicant and assuming control. The Board was reconstituted with members nominated by Dhanuka, including Mr. Ram Gopal Agarwal (Chairman) and Mr. Manish Dhanuka (Managing Director), both from the Dhanuka Group. The company's go-to-market motion is sales-led and B2B-oriented, relying on direct alliances with pharmaceutical partners rather than disclosed direct-to-consumer channels. Revenue figures are not publicly disclosed, and the company's current operational scale post-resolution is not quantified in available sources.

Name

Orchid Chemicals & Pharmaceuticals Ltd.

Legal name

OrchidPharma Ltd

Website

https://orchidpharma.com

Company type

Public

Founded year

1992

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

OrchidPharma Ltd is a vertically integrated Indian pharmaceutical manufacturer founded in 1992, producing APIs and finished dosage forms across multiple therapeutic segments and serving approximately 50 pharmaceutical companies through B2B alliances. Now under Dhanuka Laboratories Limited ownership following 2020 CIRP resolution.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industries

Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts) (AFAJAKAD), Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Active pharmaceutical ingredients
• Finished dosage forms
• Generic pharmaceuticals
• Anti-infective formulations
• Nutraceutical products

Headquarters

HQ city

Chennai

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Active Pharmaceutical Ingredients (API): Manufacturing and sale of active pharmaceutical ingredients for various therapeutic applications
2. Finished Dosage Forms: Manufacturing and marketing of finished pharmaceutical products across multiple therapeutic segments

Go-to-market motion1 record

Distribution channels1 record

Core offering

OrchidPharma is a vertically integrated pharmaceutical manufacturer that produces Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (oral and sterile products) across multi-therapeutic segments including anti-infectives, anti-inflammatory, CNS, cardiovascular, and nutraceuticals. It supplies these products to approximately 50 pharmaceutical companies in India through alliances and partnerships with globally reputed majors, leveraging an integrated value chain from discovery to delivery.

Product overview

Orchid Pharma Ltd. is a vertically integrated pharmaceutical company operating across the entire value chain from discovery to delivery. The company's product portfolio comprises two core offerings: Active Pharmaceutical Ingredients (APIs) serving as the foundational raw materials for pharmaceutical formulations, and Finished Dosage Forms including oral and sterile products. The company maintains multi-therapeutic presence across anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular (CVS), and nutraceuticals segments. Globally present across approximately 50 pharmaceutical companies in India through strategic alliances and partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (API) Active Pharmaceutical Ingredients (APIs) manufactured for global pharmaceutical companies, serving as the foundational raw material for finished dosage forms across multiple therapeutic segments including anti-infectives, anti-inflammatory, CNS, cardiovascular, and nutraceuticals.
• Finished Dosage Forms Finished dosage forms including oral and sterile products, representing the final pharmaceutical formulations across multi-therapeutic segments (anti-infectives, anti-inflammatory, CNS, cardiovascular, nutraceuticals) supplied to pharmaceutical companies and partners.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Aurobindo Pharma: Aurobindo is a vertically integrated Indian pharma with leading API manufacturing and a broad finished-dose portfolio across anti-infectives, CNS, and CVS — directly overlapping Orchid's therapeutic and business-model footprint.
• Divi's Laboratories: Divi's is one of India's largest API manufacturers with deep capabilities in generic APIs and intermediates, mirroring Orchid's core API business and export orientation.
• Dr. Reddy's Laboratories: Dr. Reddy's is an integrated Indian pharma with global generics, APIs, and biosimilars, serving overlapping therapeutic segments (anti-infectives, CNS, CVS) and competing for similar international partnership contracts.
• Lupin: Lupin is an Indian pharma with strong API and finished-dose operations in anti-infectives, CNS, and CVS, directly comparable to Orchid's product mix and global B2B distribution model.
• Cipla: Cipla is one of India's largest vertically integrated pharma companies with strength in anti-infectives, respiratory, and CNS — overlapping therapeutic and geographic coverage with Orchid.
• Cadila Healthcare (Zydus): Zydus operates a fully integrated API-to-formulations model in India with a comparable therapeutic portfolio, making it a close comparable for Orchid's vertically integrated business model.
• Glenmark Pharmaceuticals: Glenmark is an India-headquartered pharma with API and finished formulations across multiple therapeutic areas, including branded generics in emerging markets similar to Orchid's footprint.

Emerging players

• Strides Pharma: Strides focuses on finished-dose generics, including oral and sterile injectables, with emerging markets exposure — closely aligned with Orchid's sterile products business but with a narrower API footprint.
• Biocon: Biocon is an India-based biopharmaceutical company with APIs, generics, and biosimilars, providing a peer benchmark for the biologics and complex generics adjacencies where Orchid could expand.

Broad incumbents

• Sun Pharmaceutical Industries: Sun Pharma is India's largest pharma company with broad therapeutic, API, and formulation capabilities; a clear market leader and benchmark for Indian pharma scale and competitiveness.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/orchid-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orchid Chemicals & Pharmaceuticals Ltd.